ZNF384-related fusion genes in acute lymphoblastic leukemia
L Zhu, W Bai, Q Cheng, J Fang - Cancer Control, 2023 - journals.sagepub.com
Zinc finger protein 384 (ZNF384) encodes a C2H2-type zinc finger protein that can function
as a transcription factor. ZNF384 rearrangement in acute lymphoblastic leukemia (ALL) was …
as a transcription factor. ZNF384 rearrangement in acute lymphoblastic leukemia (ALL) was …
CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch
BJ Lee, SP Griffin, J Doh, A Chan… - American Journal of …, 2022 - Wiley Online Library
To the Editor: Acute lymphoblastic leukemia (ALL) bearing the KMT2A-rearrangement is a
high-risk genomic subgroup, characterized by chemotherapy-resistance and a propensity for …
high-risk genomic subgroup, characterized by chemotherapy-resistance and a propensity for …
Reliable flow-cytometric approach for minimal residual disease monitoring in patients with B-cell precursor acute lymphoblastic leukemia after CD19-targeted therapy
E Mikhailova, O Illarionova, A Komkov, E Zerkalenkova… - Cancers, 2022 - mdpi.com
Simple Summary We aimed to develop an antibody panel and data analysis algorithm for
multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease …
multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease …
Recognizing minor leukemic populations with monocytic features in mixed-phenotype acute leukemia by flow cell sorting followed by cytogenetic and molecular …
A Semchenkova, E Zerkalenkova, I Demina… - International Journal of …, 2023 - mdpi.com
Mixed-phenotype acute leukemia (MPAL), a rare and heterogeneous category of acute
leukemia, is characterized by cross-lineage antigen expression. Leukemic blasts in MPAL …
leukemia, is characterized by cross-lineage antigen expression. Leukemic blasts in MPAL …
KMT2A-rearranged leukemia: the shapeshifter
I Iacobucci, CG Mullighan - Blood, The Journal of the American …, 2022 - ashpublications.org
Shapeshifters, sceadugengan, shadow walkers: these are characters ubiquitous in
mythology that can physically transform, from human to beast, for example, to trick, frustrate …
mythology that can physically transform, from human to beast, for example, to trick, frustrate …
Novel bimodal TRBD1-TRBD2 rearrangements with dual or absent D-region contribute to TRB V-(D)-J combinatorial diversity
AO Smirnova, AM Miroshnichenkova… - Frontiers in …, 2023 - frontiersin.org
T-cell receptor (TR) diversity of the variable domains is generated by recombination of both
the alpha (TRA) and beta (TRB) chains. The textbook process of TRB chain production starts …
the alpha (TRA) and beta (TRB) chains. The textbook process of TRB chain production starts …
Диагностическое иммунофенотипирование острых лейкозов. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов …
АМ Попов, ТЮ Вержбицкая, ЛВ Мовчан… - … и иммунопатологии в …, 2023 - hemoncim.com
Аннотация На сегодняшний день данные иммунофенотипирования используются для
диагностики острых лейкозов (ОЛ), стратификации пациентов в рамках крупных …
диагностики острых лейкозов (ОЛ), стратификации пациентов в рамках крупных …
Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia
K Bełdzińska-Gądek, E Zarzycka… - Leukemia & …, 2024 - Taylor & Francis
Acute leukemia (AL) with a lineage switch (LS) is associated with poor prognosis. The
predisposing factors of LS are unknown, apart from KMT2A rearrangements that have been …
predisposing factors of LS are unknown, apart from KMT2A rearrangements that have been …
Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement
M Suematsu, S Yagyu, H Yoshida, S Osone… - Cancer Immunology …, 2023 - Springer
CD19-specific chimeric antigen receptor T (CAR T) immunotherapy is used to treat B-cell
malignancies. However, antigen-escape mediated relapse following CAR T therapy has …
malignancies. However, antigen-escape mediated relapse following CAR T therapy has …
Рекомендации по определению минимальной остаточной болезни методом проточной цитометрии при остром В-лимфобластном лейкозе в условиях …
ЕВ Михайлова, ОИ Илларионова… - … и иммунопатологии в …, 2023 - hemoncim.com
Аннотация Многоцветная проточная цитометрия широко используется в современной
лабораторной практике для определения минимальной остаточной болезни (МОБ) у …
лабораторной практике для определения минимальной остаточной болезни (МОБ) у …